WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
New York Rangers captain Jacob Trouba may be the most interesting man in hockey, on and off the iceNelly Korda 1 shot back through 36 holes at Chevron Championship as she chases 5th straight victory'The Full English will never die out!' Greasy spoon fans speak up for the Great British FryCoyotes' move to Salt Lake City elicits opposing responses in 2 citiesOlympic torch makes Acropolis overnight stop a week before handover to Paris organizersThe prosecution team in Alec Baldwin's 'Rust' trial has a new attorneyThe EPA is again allowing summer sales of higher ethanol gasoline blend, citing global conflictsThe EPA is again allowing summer sales of higher ethanol gasoline blend, citing global conflictsChina's BYD adds new dealership in TokyoWorker electrocuted while doing maintenance on utility pole in upstate New York